A 38-year-old man presents with acute pancreatitis secondary to gallstones. On day 3 of hospitalization, he develops fever (38.5°C), elevated inflammatory markers, and imaging confirms pancreatic necrosis with gas-forming organisms. He is haemodynamically stable and on broad-spectrum antibiotics. What is the drug of choice for targeted antimicrobial coverage in infected pancreatic necrosis?

## Antimicrobial Therapy in Infected Pancreatic Necrosis ### Pathophysiology & Clinical Context Infected pancreatic necrosis occurs in 10–30% of patients with acute pancreatitis and represents a surgical emergency. Gas-forming organisms (E. coli, Klebsiella, Staphylococcus, Clostridium) indicate secondary infection of necrotic tissue. The infected necrotic tissue has poor vascularization, limiting antibiotic penetration. ### Why Meropenem is the Drug of Choice **Key Point:** Meropenem is a broad-spectrum carbapenem with superior pancreatic tissue penetration and excellent coverage of gram-negative, gram-positive, and anaerobic organisms implicated in infected necrosis. **High-Yield:** Carbapenems (meropenem, imipenem) achieve high concentrations in pancreatic tissue and necrotic fluid due to their lipophilic properties and broad spectrum. They cover: - Gram-negative aerobes (E. coli, Klebsiella, Pseudomonas) - Gram-positive cocci (Staphylococcus, Streptococcus) - Anaerobes (Bacteroides, Clostridium) **Clinical Pearl:** In infected pancreatic necrosis, monotherapy with a carbapenem is often sufficient and preferred over combination regimens because single-agent coverage is complete and tissue penetration is superior. ### Comparison with Alternatives | Agent | Spectrum | Pancreatic Penetration | Role in Infected Necrosis | |-------|----------|------------------------|---------------------------| | **Meropenem** | Gram-neg, gram-pos, anaerobic | Excellent (lipophilic) | **First-line** | | Ceftriaxone + Metronidazole | Good but cephalosporin gaps vs. Pseudomonas | Moderate | Acceptable alternative if carbapenem unavailable | | Ciprofloxacin + Clindamycin | Fluoroquinolone gaps in gram-pos coverage | Moderate | Suboptimal; ciprofloxacin monotherapy insufficient | | Ampicillin + Gentamicin | Limited anaerobic coverage; aminoglycoside nephrotoxicity risk | Poor | Outdated regimen; inadequate for polymicrobial infection | **Warning:** Cephalosporins (ceftriaxone, cefotaxime) have poor activity against Pseudomonas and variable anaerobic coverage — not ideal monotherapy for infected necrosis. ### Clinical Management Algorithm ```mermaid flowchart TD A[Acute Pancreatitis + Fever/Sepsis on Day 3+]:::outcome --> B{Imaging: Infected Necrosis?}:::decision B -->|Yes + Haemodynamically stable| C[Start Meropenem IV]:::action B -->|Yes + Septic shock| D[Meropenem + Source Control]:::action C --> E[Continue 2-4 weeks]:::action D --> F[Consider Step-Down Therapy]:::action E --> G[Clinical & Imaging Response]:::outcome F --> G ``` **Key Point:** Duration of antibiotic therapy is typically 2–4 weeks, guided by clinical response and imaging resolution of necrosis. ### Additional Considerations - **Imipenem** is an acceptable alternative to meropenem but carries slightly higher seizure risk in high doses. - **Ertapenem** has narrower spectrum (no Pseudomonas) and is not recommended for infected necrosis. - **Prophylactic antibiotics** in sterile acute pancreatitis (without necrosis) are NOT routinely recommended; they are reserved for infected necrosis. [cite:Harrison 21e Ch 346]